Edition:
United States

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

8.40USD
4:00pm EDT
Change (% chg)

$0.15 (+1.82%)
Prev Close
$8.25
Open
$8.24
Day's High
$8.47
Day's Low
$8.15
Volume
18,185
Avg. Vol
76,416
52-wk High
$23.68
52-wk Low
$5.92

Chart for

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing... (more)

Overall

Beta: --
Market Cap(Mil.): $197.29
Shares Outstanding(Mil.): 23.91
Dividend: --
Yield (%): --

Financials

  PTGX.OQ Industry Sector
P/E (TTM): -- 107.68 32.65
EPS (TTM): -1.21 -- --
ROI: -28.54 1.61 12.72
ROE: -28.69 0.32 14.84

BRIEF-Protagonist Therapeutics Reports Q1 Net Loss Per Share $0.36

* PROTAGONIST THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100

* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS

Mar 26 2018

Earnings vs. Estimates